Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

10.74 +0.08 (+0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,495,238
Open 10.60
Bid (Size) 10.68 (1)
Ask (Size) 10.84 (16)
Prev. Close 10.66
Today's Range 10.38 - 10.79
52wk Range 6.080 - 11.93
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems. 
Via InvestorPlace
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace

Performance

YTD
+27.25%
+27.25%
1 Month
+69.67%
+69.67%
3 Month
+19.07%
+19.07%
6 Month
+19.87%
+19.87%
1 Year
+8.81%
+8.81%

More News

Read More
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Via The Motley Fool
3 Long-Term Growth Stocks Analysts Are Bullish On
Via InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
Via InvestorPlace
A Preview Of Editas Medicine's Earnings
Via Benzinga
Analyst Ratings for Editas Medicine
Via Benzinga
Is Editas Stock a Buy Now?
Via The Motley Fool
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For November 3, 2023
Via Benzinga
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
Via The Motley Fool
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene Editing Stocks to Generate Super-Charged Gains
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Via The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.